In mild of those challenges, there may be an pressing must determine insurance coverage reforms that may meaningfully enhance entry to inexpensive, high-quality take care of sufferers with blood most cancers. To evaluate the present proof base for such reforms, we carried out a literature assessment and hole evaluation. Our goals had been, first, to determine and categorize present proof concerning the affect of medical insurance standing and kind on entry to care and outcomes amongst sufferers with blood most cancers, and second, to determine areas of uncertainty and key analysis gaps.
We carried out a scientific search of Medline’s PubMed database on June 5, 2020, and an extra focused writer search on July 1, 2020. Search phrases included related Medical Topic Headings in addition to related blood most cancers and insurance coverage key phrases. Search phrases had been recognized by reviewing key phrases in latest insurance coverage and blood most cancers publications and had been developed in collaboration with consultants and in session with an info scientist. The search was supplemented by reviewing the bibliographies of any recognized assessment articles. The mixed searches yielded 1101 articles. To determine the subset of related publications that may inform policymakers and the scientific subject of the insurance coverage analysis panorama associated to blood most cancers care and outcomes, we screened titles and abstracts for eligibility towards a set of inclusion and exclusion standards. Research had been eligible for inclusion in the event that they concerned sufferers with blood most cancers at any stage on the most cancers care continuum and had a give attention to insurance coverage. We included research with insurance coverage as the first focus of the research and research through which insurance coverage was a variable or an end result of the research. All research designs had been eligible, together with assessment articles and qualitative analysis. We excluded research particularly centered on cancers apart from blood most cancers however included basic most cancers research in the event that they had been identified to or very more likely to embrace sufferers with blood most cancers. We excluded research printed earlier than January 2000, these carried out exterior of america (or its territories), and people not within the English language. We additionally excluded animal and in vitro research, letters to the editor, and publication feedback.
To offer an summary of the out there scientific literature and a niche evaluation to determine areas of uncertainty and analysis which can be lacking or underrepresented, we categorized included articles utilizing the inhabitants, intervention, comparator, and outcomes framework9 to construction information abstraction.
Given the scope and goal of the assessment, categorization was primarily based on a assessment of abstracts
by a single analysis analyst and high quality checked by a senior methodologist. We didn’t conduct a risk-of-bias evaluation, and we retrieved full texts just for research that didn’t embrace an summary or when related info was not introduced within the summary. Abstracted classes included research title, writer, publication 12 months, pattern measurement, research design, most cancers focus, inhabitants group, insurance coverage kind, most cancers continuum, comparator, and end result. For every class, we established predefined coding variables and abstracted the principle insurance-related end result discovering right into a free-text subject. The categorization course of was primarily carried out on the data out there within the research summary.
Overview of the Analysis Panorama
Following title and summary assessment, we recognized 154 publications for inclusion, 70 of which had a direct give attention to insurance coverage as the topic of the article; of these, 39 centered particularly on blood cancers. Research had been predominantly giant retrospective cohort research usually utilizing Medicare claims information or the Nationwide Most cancers Institute–funded Surveillance, Epidemiology, and Finish Outcomes (SEER) registry information or SEER-Medicare information as the idea for evaluation. Virtually half of the retrospective research centered on the affiliation between insurance coverage standing or kind and an end result of curiosity. The rest reported insurance coverage as certainly one of a number of components discovered to be related to a medical end result (eg, survival), high quality of most cancers care, or entry to therapy. One potential cohort research assessed the standard of most cancers take care of older sufferers offered by the Veterans Well being Administration vs fee-for-service Medicare.10 Of two recognized systematic opinions, one 2005 research was particular to blood most cancers and located (from very restricted quality-of-life [QOL] information) that people with power lymphocytic leukemia expertise challenges acquiring medical insurance.11 The opposite was a latest 2020 systematic assessment that investigated proof associated to medical insurance protection disruptions and most cancers outcomes and located that these sufferers with protection disruption had been extra more likely to have superior illness, be much less more likely to obtain therapy, and have worse survival than their counterparts with out protection disruptions.12
Greater than half of the recognized research addressed a number of sorts of insurance coverage, and Medicare was the main target of 16% of research. Medicaid was hardly ever studied as the only focus of a research. Research with a give attention to adults (65 years and youthful) had been most typical, addressed in one-third of all included research, adopted by adolescents and younger adults (addressed in 21% of research) and older adults (addressed in 19%). Youngsters had been a spotlight of simply 9% of included research, and a handful of research weren’t centered on any affected person inhabitants however fairly on doctor opinion or practices.13-15 Of the 39 research particular to blood most cancers and insurance coverage, none particularly centered on various racial and ethnic teams or sufferers in rural settings.
Research tended to give attention to sufferers in lively therapy, addressed by 42% of all included research.
Survivorship was additionally generally studied, addressed in virtually 1 / 4 of research. Notably, simply 2 research addressed therapy within the context of medical trial participation, certainly one of which particularly centered on sufferers with blood most cancers.16 A 2014 case research by Preussler and colleagues highlighted state variation in Medicaid protection of complicated oncology therapies for blood most cancers and located that just a few states offered the really helpful advantages (ie, advantages suggestions developed by a number of stakeholders) for hematopoietic cell transplantation medical trial protection.16
Mortality/survival and entry to care had been among the many outcomes most frequently studied, addressed in 35% and 33% of the 154 included research, respectively. Research addressing entry to care had been broad and included the affect of insurance coverage standing and kind on receipt of or timeliness of therapy; well being care utilization; and entry to specialist care, high-cost therapies, and monetary help corresponding to cost-sharing subsidies. Only a few research centered on the connection between insurance coverage protection and the incidence of treatment-related adversarial occasions (TRAEs) or most cancers recurrence, and amongst research particularly centered on blood cancers, only a few addressed the connection between insurance coverage and high quality of care or QOL. Equally, only a few research investigated insurance-related disparities in well being outcomes primarily based on race/ethnicity or on socioeconomic components.
Key Insurance coverage-Associated Findings and Gaps Particular to Blood Most cancers
Insurance coverage and survival. Fifty-six % of research that centered particularly on blood most cancers and insurance coverage (22 of 39) reported survival as an end result of curiosity. Of those, 21 examined the affect of insurance coverage standing or kind on survival (Desk). Seventeen research discovered disparities in general survival (OS) primarily based on insurance coverage standing and kind,17-32 2 reported no distinction in OS primarily based on insurance coverage kind,33,34 and a couple of reported combined findings.35,36 All however one research reporting survival disparities had been giant retrospective registry research, and overwhelmingly, they reported higher survival amongst sufferers with insurance coverage in contrast with these with no insurance coverage and higher survival amongst sufferers with personal business insurance coverage in contrast with different insurance coverage varieties. In distinction, the two research reporting no distinction in OS primarily based on insurance coverage kind had been small chart opinions.33,34
Of the two research reporting combined survival outcomes, each had been giant registry database research.
One discovered elevated OS amongst Medicaid-enrolled beneficiaries in contrast with non–Medicaid-enrolled beneficiaries (with the non-Medicaid group together with each commercially insured and uninsured sufferers) with acute myeloid leukemia and Hodgkin lymphoma enrolled in New York State; nonetheless, there was no such distinction in survival amongst Medicaid beneficiaries enrolled in California.35 In a 2015 research, Olszewski and Foran discovered that when confounding components are thought-about, insurance-associated lymphoma survival disparities are partly mediated by the prevalence of identified prognostic components or by sufferers’ preexisting medical circumstances that on the time drove eligibility for Medicaid and Medicare; these authors famous that most cancers registries typically don’t comprise details about comorbidities or different confounders.36
One research assessed the timeliness of care (outlined as time from payer approval to precise HCT) and its affect on OS for sufferers who underwent hematopoietic cell transplantation (HCT).37 Complete time to HCT was longer for sufferers insured by public payers than for these with personal insurance coverage (median, 66 days [range, 14-277] vs 48 days [range, 1-407]; P < .001), however timeliness was not related to OS.37
Insurance coverage and monetary burden. 13 of 39 research that centered particularly on blood most cancers included monetary burden as an end result of curiosity.17,38-49 Total, the findings level to a major insurance-related monetary burden for sufferers with blood most cancers. Notably, most research addressed monetary burden amongst Medicare beneficiaries, whereas few research investigated the scale and affect of the monetary burden positioned on uninsured sufferers and Medicaid beneficiaries with blood most cancers. Of 13 research, 8 centered on Medicare Half D. Of those, 5 reported elevated monetary burden on sufferers associated particularly to excessive cost-sharing beneath Medicare Half D,41-45 3 of which additionally reported that prime cost-sharing beneath Medicare Half D was related to lowered or delayed initiation of specialty medication (ie, tyrosine kinase inhibitors [TKIs]).41-43 The opposite 3 research addressing Medicare Half D checked out low-income subsidies amongst recipients; one discovered that amongst Medicare beneficiaries with out low-income subsidies, the introduction of Medicare Half D reductions offered through the Half D protection hole part decreased sufferers’ monetary burden46; the second reported a considerable monetary barrier to accessing orally administered anticancer remedy for these not receiving low-income subsidies.47 The third research discovered that in contrast with Medicare Half D recipients who didn’t obtain low-income subsidies, these sufferers who had been closely or reasonably backed demonstrated higher nonadherence to TKI therapy.48 This research demonstrated an affiliation between low-income subsidies and nonadherence however didn’t declare that low-income subsidies trigger nonadherence.48 Unrelated to Medicare Half D, a small research discovered that amongst 20 US most cancers middle administrators and chief medical officers surveyed, 15 had been involved in regards to the monetary viability of their chimeric antigen receptor T-cell immunotherapy applications, citing Medicare reimbursement charges and producer costs as the first drivers of viability considerations.40
Two research reported monetary burden for these with business medical insurance. A 2014 research
reported on the monetary burden related to greater copayments,49 and a 2001 (pre-ACA) research
reported that 61% of survey respondents paid out of pocket for some facet of medical care that was not lined by their medical insurance protection following a analysis of bushy cell leukemia.39 Only one research from 2015 reported on the monetary burden for Medicaid beneficiaries with blood most cancers,38 and a 2011 research reported on the prices of inpatient therapy for uninsured sufferers with acute myeloid leukemia.17
Entry to insurance coverage. Just a few research analyzing pre-ACA information highlighted the problem in acquiring
medical insurance (or in navigating gaps in insurance coverage) following a blood most cancers analysis.39,50,51 Increasing entry to complete medical insurance protection was a major mission of the ACA,1 and now, publish ACA, a blood most cancers analysis is not the menace it as soon as was to a affected person’s skill to enroll and keep enrolled in a well being plan. Though a number of research have examined the affect of the ACA on insurance coverage protection and insurance-related outcomes pre- and publish implementation, just one pre-post ACA research was discovered to have centered on a inhabitants of sufferers with blood most cancers. In a 2019 registry research, Ramachandran and colleagues noticed no
distinction within the charges of newly recognized cutaneous T-cell lymphoma by insurance coverage kind (outlined as uninsured, Medicaid insured, and non-Medicaid insured) earlier than and after full implementation of the ACA.52 This was true when wanting throughout all states, whether or not Medicaid growth or nonexpansion states.52 Additionally associated to entry, one research discovered that lack of insurance coverage was related to superior stage of Hodgkin lymphoma analysis.53
Insurance coverage and medical trial entry. Just one research checked out insurance-related entry to medical
trial participation for sufferers with blood most cancers. A 2014 case research investigating the variation in Medicaid insurance policies amongst states in 2012 discovered that just a few states offered the really helpful advantages (ie, really helpful advantages developed by a number of stakeholders) for hematopoietic cell transplantation medical trial protection.16
Insurance coverage and race/ethnicity. A lot of research reported an affiliation between race/ethnicity and blood most cancers outcomes, with poorer outcomes for sufferers who’re Hispanic, African American and non-Hispanic Black.17,29,30,35,53 Nevertheless, simply 2 examined whether or not race/ethnicity remained related to various outcomes after adjusting for insurance coverage standing,35,53 and each discovered that race/ethnicity was not considerably related to blood most cancers outcomes when regression fashions had been adjusted for insurance coverage standing.16
Insurance coverage and different outcomes. Solely a handful of blood most cancers–particular research addressed high quality
of care16,41,46,53 or health-related QOL (HRQOL)39 as outcomes of curiosity, and these weren’t major outcomes of any of the recognized research. The connection between these outcomes and insurance coverage standing amongst sufferers with blood most cancers stays largely unknown.
Dialogue/Gaps within the Present Proof
A modest physique of scientific proof means that survival amongst sufferers with blood most cancers is
affected by insurance coverage standing and kind, with higher OS among the many insured vs the uninsured and higher OS amongst these with business insurance coverage vs public insurance coverage. Equally, research of registry and claims information counsel a major insurance-related monetary burden for sufferers with blood most cancers.
Nevertheless, a lot of limitations are related to the prevailing literature, which finally hinder
the event of evidence-based policymaking on this space. Proof of the associations amongst insurance coverage standing, insurance coverage kind, survival, and monetary burden are primarily based totally on retrospective cohort research that will fail to regulate for comorbidities and confounders. Further research, together with potential cohort research and huge well-controlled registry research inspecting the affect of insurance coverage on survival and monetary burden, may verify present findings and delve into key subgroups. Virtually no present analysis is targeted on necessary outcomes past survival and monetary burden, such because the affect of insurance coverage on medical trial participation, high quality of care, HRQOL outcomes, TRAEs, and most cancers recurrence. Entry to trials, particularly, has been of longstanding curiosity to policymakers; Congress just lately handed the Medical Therapy Act to enhance trial-related protection for Medicaid beneficiaries. Implementation of this legislation could be enhanced by analysis exploring whether or not uninsurance or underinsurance may proceed to behave as a barrier to trial participation sooner or later, in addition to the reforms that may be wanted to handle such boundaries in full.
Few research have centered on various racial and ethnic teams, sufferers with low revenue, Medicaid beneficiaries, uninsured sufferers, and sufferers residing in rural settings. Equally, comparatively few research have centered on adolescents and younger adults, and simply 14 research (9%) centered on households with a pediatric affected person. Consequently, little is understood in regards to the affect of insurance coverage on blood most cancers care inside these weak populations. Though policymakers have expressed commitments to addressing well being disparities, evidence-based policymaking on this space will probably be constrained by the gaps on this literature.
No peer-reviewed research have examined blood most cancers outcomes associated to short-term, limited-duration well being plans and different sorts of insurance-like merchandise (eg, mounted indemnity plans or well being care sharing ministries) that don’t adjust to the ACA’s market reforms and thus require plan enrollees to imagine vital monetary threat. With a number of million individuals already enrolled in a few of these plan varieties,54 it’s important to know the extent to which such protection contributes to large-scale monetary toxicity for sufferers residing with expensive illnesses like blood most cancers.
No research have evaluated the implementation of interventions designed to enhance entry to or use of insurance coverage amongst sufferers with blood most cancers (eg, affected person navigators centered on insurance coverage entry; insurance-related teaching programs). Implementation analysis ought to study the strategies and methods that facilitate the uptake of evidence-based insurance-related applications and pointers into apply. Such analysis could be well timed as a result of the Biden administration has recognized elevated enrollment in certified well being plans as essential to stabilize the ACA’s insurance coverage marketplaces, and policymakers have just lately expressed a want to curb dealer practices that steer unwitting sufferers to inferior medical insurance plans.54
The present physique of peer-reviewed literature supplies proof that insurance coverage standing and kind have an effect on OS and monetary burden for sufferers with blood most cancers. Nevertheless, proof is inadequate on the affect of insurance coverage on different necessary outcomes, together with medical trial participation, high quality of care, and HRQOL. As well as, proof particular to key weak populations is inadequate. Additional analysis is required to information policymaking in these areas and to assist sufferers successfully navigate the medical insurance market, acquire higher entry to high-quality care, and obtain higher well being outcomes.
AUTHOR INFORMATION. Karen Crotty, Katherine Treiman, Candi Wines, and Catherine Viator are with RTI Worldwide; Marialanna Lee, Maria Sae-Hau, and Elisa Weiss are with The Leukemia &
CORRESPONDING AUTHOR: Karen Crotty, RTI Worldwide, 3040 E Cornwallis Street, Hobbs 139, P.O. Field 12194, Durham, NC 27709. E-mail: email@example.com.
FUNDING SOURCE. This work was funded by The Leukemia & Lymphoma Society.
1. Zhao J, Mao Z, Fedewa SA, et al. The Inexpensive Care Act and entry to care throughout the most cancers management continuum: a assessment at 10 years. CA Most cancers J Clin. 2020;70(3):165-181. doi:10.3322/caac.21604
2. Hong Y-R, Smith GL, Xie Z, Mainous AG III, Huo J. Monetary burden of most cancers care beneath the Inexpensive Care Act: evaluation of MEPS–
experiences with most cancers survivorship 2011 and 2016. J Most cancers Surviv. 2019;13(4):523-536. doi:10.1007/s11764-019-00772-y
3. Carrera PM, Kantarjian HM, Blinder VS. The monetary burden and misery of sufferers with most cancers: understanding and stepping-up motion on the monetary toxicity of most cancers therapy. CA Most cancers J Clin. 2018;68(2):153-165. doi:10.3322/caac.21443
4. Lentz R, Benson AB III, Kircher S. Monetary toxicity in most cancers care: prevalence, causes, penalties, and discount methods. J Surg Oncol. 2019;120(1):85-92. doi:10.1002/jso.25374
5. Dusetzina SB, Huskamp HA, Keating NL. Specialty drug pricing and out-of-pocket spending on orally administered anticancer medication in Medicare Half D, 2010 to 2019. JAMA. 2019;321(20):2025-2027. doi:10.1001/jama.2019.4492
6. Howlader N, Noone AM, Krapcho M, et al. SEER Most cancers Statistics Assessment, 1975-2016. Nationwide Most cancers Institute/Surveillance, Epidemiology, and Finish Outcomes Program. Up to date April 9, 2020. Accessed July 28, 2021. https://seer.most cancers.gov/archive/csr/1975_2016/
7. Dieguez G, Ferro C, Rotter D. Milliman Analysis Report: the associated fee burden of blood most cancers care: a longitudinal evaluation of commercially insured sufferers diagnoses with blood most cancers. Leukemia & Lymphoma Society. October 2018. Accessed March 2, 2021. https://www.lls.org/websites/
8. Palanker D, Lucia Ok, Goe CL. Alternatives to higher defend customers and markets from the unfavourable affect of short-term plans. The Commonwealth Fund. January 14, 2021. Accessed January 31, 2021. https://www.commonwealthfund.org/weblog/2021/opportunities-better-protect-
9. Samson D, Schoelles KM. Growing the subject and structuring systematic opinions of medical exams: utility of PICOTS, analytic frameworks, resolution timber, and different frameworks. In: Chang S, Matchar DB, Smetana GW, Umscheid CA, eds. Strategies Information for Medical Take a look at Critiques
[Internet]. Rockville (MD): Company for Healthcare Analysis and High quality (US); 2012 Jun:chapter 2.
10. Keating NL, Landrum MB, Lamont EB, et al. High quality of take care of older sufferers with most cancers within the Veterans Well being Administration versus the personal sector: a cohort research. Ann Intern Med. 2011;154(11):727-736. doi:10.7326/0003-4819-154-11-201106070-00004
11. Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL. Persistent lymphocytic leukemia: financial burden and high quality of life: literature assessment. Am J Ther. 2005;12(5):460-466. doi:10.1097/01.mjt.0000104489.93653.0f
12. Yabroff KR, Reeder-Hayes Ok, Zhao J, et al. Medical insurance protection disruptions and most cancers care and outcomes: systematic assessment of printed analysis. J Natl Most cancers Inst. 2020;112(7):671-687. doi:10.1093/jnci/djaa048
13. Pidala J, Craig BM, Lee SJ, Majhail N, Quinn G, Anasetti C. Follow variation in doctor referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48(1):63-67. doi:10.1038/bmt.2012.95
14. Schaefer NG, Huang P, Buchanan JW, Wahl RL. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear drugs physicians and radiation oncologists. J Nucl Med. 2011;52(5):830-838. doi:10.2967/jnumed.110.085589
15. Dusetzina SB, Basch E, Keating NL. For uninsured most cancers sufferers, outpatient fees may be expensive, placing therapies out of attain. Well being Aff (Millwood). 2015;34(4):584-591. doi:10.1377/hlthaff.2014.0801
16. Preussler JM, Farnia SH, Denzen EM, Majhail NS. Variation in Medicaid protection for hematopoietic cell transplantation. J Oncol Pract. 2014;10(4):e196-e200. doi:10.1200/jop.2013.001155
17. Bradley CJ, Dahman B, Jin Y, Shickle LM, Ginder GD. Acute myeloid leukemia: how the uninsured fare. Most cancers. 2011;117(20):4772-4778. doi:10.1002/cncr.26095
18. Colton MD, Goulding D, Beltrami A, et al. A U.S. population-based research of insurance coverage disparities in most cancers survival amongst adolescents and younger adults. Most cancers Med. 2019;8(10):4867-4874. doi:10.1002/cam4.2230
19. Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ. Prescription drug protection and outcomes of myeloma remedy amongst Medicare beneficiaries. J Clin Oncol. 2018;36(28):2879-2886. doi:10.1200/jco.2018.77.8894
20. Goldstein JS, Nastoupil LJ, Han X, Jemal A, Ward E, Flowers CR. Disparities in survival by insurance coverage standing in follicular lymphoma. Blood. 2018;132(11):1159-1166. doi:10.1182/blood-2018-03-839035
21. Tang R, Su C, Bai HX, et al. Affiliation of insurance coverage standing with survival in sufferers with cutaneous T-cell lymphoma. Leuk Lymphoma.
22. Pulte D, Castro FA, Brenner H, Jansen L. End result disparities by insurance coverage kind for sufferers with acute myeloblastic leukemia. Leuk Res. 2017;56:75-81. doi:10.1016/j.leukres.2017.02.001
23. Perry AM, Brunner AM, Zou T, et al. Affiliation between insurance coverage standing at analysis and general survival in power myeloid leukemia: a population-based research. Most cancers. 2017;123(13):2561-2569. doi:10.1002/cncr.30639
24. Ortiz-Ortiz KJ, Ortiz-Martínez de Andino JJ, Torres-Cintrón CR, et al. Impact of kind of medical insurance protection on leukemia survival in adults in Puerto Rico. P R Well being Sci J. 2014;33(3):132-135.
25. Fintel AE, Jamy O, Martin MG. Affect of insurance coverage and marital standing on outcomes of adolescents and younger adults with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(6):364-367. doi:10.1016/j.clml.2014.12.006
26. Grasp S, Munker R, Shi Z, Mills G, Shi R. Insurance coverage standing and different non-biological components predict outcomes in acute myelogenous leukemia: evaluation of knowledge from the Nationwide Most cancers Database. Anticancer Res. 2016;36(9):4915-4921. doi:10.21873/anticanres.11057
27. Selby GB, Ali LI, Carter TH, Veseley S, Roy V. The affect of medical insurance on outcomes of related-donor hematopoietic stem cell transplantation for AML and CML. Biol Blood Marrow Transplant. 2001;7(10):576. doi:10.1016/s1083-8791(01)70018-3
28. Pulte D, Jansen L, Brenner H. Survival disparities by insurance coverage kind for sufferers aged 15-64 years with non-Hodgkin lymphoma. Oncologist. 2015;20(5):554-561. doi:10.1634/theoncologist.2014-0386
29. Costa LJ, Brill IK, Brown EE. Impression of marital standing, insurance coverage standing, revenue, and race/ethnicity on the survival of youthful sufferers recognized with a number of myeloma in america. Most cancers.
30. Keegan TH, DeRouen MC, Parsons HM, et al. Impression of therapy and insurance coverage on socioeconomic disparities in survival after adolescent and younger grownup Hodgkin lymphoma: a population-based research. Most cancers Epidemiol Biomarkers Prev. 2016;25(2):264-273. doi:10.1158/1055-9965. epi-15-0756
31. Han X, Jemal A, Flowers CR, Sineshaw H, Nastoupil LJ, Ward E. Insurance coverage standing is said to diffuse giant B-cell lymphoma survival. Most cancers. 2014;120(8):1220-1227. doi:10.1002/cncr.28549
32. Parikh RR, Grossbard ML, Inexperienced BL, Harrison LB, Yahalom J. Disparities in survival by insurance coverage standing in sufferers with Hodgkin lymphoma. Most cancers. 2015;121(19):3515-3524. doi:10.1002/cncr.29518
33. Srour SA, Machiorlatti M, Pierson NT, et al. Impression of well being care insurance coverage standing on therapy outcomes of acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(7):450-456.e2. doi:10.1016/j.clml.2017.05.011
34. Al-Ameri A, Anand A, Abdelfatah M, et al. End result of acute myeloid leukemia and high-risk myelodysplastic syndrome in keeping with medical insurance standing. Clin Lymphoma Myeloma Leuk. 2014;14(6):509-513. doi:10.1016/j.clml.2014.03.003
35. Yung RL, Chen Ok, Abel GA, et al. Most cancers disparities within the context of Medicaid insurance coverage: a comparability of survival for acute myeloid leukemia and Hodgkin’s lymphoma by Medicaid enrollment. Oncologist. 2011;16(8):1082-1091. doi:10.1634/theoncologist.2011-0126
36. Olszewski AJ, Foran JM. Medical insurance-related disparities in lymphoma survival are partly mediated by baseline medical components. Oncologist. 2015;20(10):1223-1224. doi:10.1634/theoncologist.2015-0228
37. Bhatt VR, Loberiza FR Jr, Schmit-Pokorny Ok, Lee SJ. Time to insurance coverage approval in personal and public payers doesn’t affect survival in sufferers who endure hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(6):1117-1124. doi:10.1016/j.
38. Huntington SF, Weiss BM, Vogl DT, et al. Monetary toxicity in insured sufferers with a number of myeloma: a cross-sectional pilot research. Lancet Haematol. 2015;2(10):e408-e416. doi:10.1016/s2352-3026(15)00151-9
39. Hounshell J, Tomori C, Newlin R, et al. Modifications in funds, insurance coverage, employment, and life-style amongst individuals recognized with bushy cell leukemia. Oncologist. 2001;6(5):435-440. doi:10.1634/theoncologist.6-5-435
40. Leech AA, Neumann PJ, Cohen JT, Jagasia M, Dusetzina SB. Balancing worth with affordability: cell immunotherapy for most cancers therapy within the US. Oncologist. 2020; 25(7):e1117-e1119. doi:10.1634/theoncologist. 2020-0025
41. Doshi JA, Li P, Huo H, et al. Excessive price sharing and specialty drug initiation beneath Medicare Half D: a case research in sufferers with newly recognized power myeloid leukemia. Am J Manag Care. 2016;22(4 Suppl):s78-s86.
42. Doshi JA, Li P, Pettit AR, Dougherty JS, Flint A, Ladage VP. Decreasing out-of-pocket price boundaries to specialty drug use beneath Medicare Half D: addressing the issue of “an excessive amount of too quickly.” Am J Manag Care. 2017;23(3 Suppl):s39-s45.
43. Winn AN, Keating NL, Dusetzina SB. Elements related to tyrosine kinase inhibitor initiation and adherence amongst Medicare beneficiaries with power myeloid leukemia. J Clin Oncol. 2016;34(36):4323-4328. doi:10.1200/jco.2016.67.4184
44. Shen C, Zhao B, Liu L, Shih Y-CT. Monetary burden for sufferers with power myeloid leukemia enrolled in Medicare Half D taking focused oral anticancer drugs. J Oncol Pract. 2017;13(2):e152-e162. doi:10.1200/jop.2016.014639
45. Davidoff AJ, Hendrick FB, Zeidan AM, et al. Affected person price sharing and receipt of erythropoiesis-stimulating brokers by way of Medicare Half D. J Oncol Pract. 2015;11(2):e190-e198. doi:10.1200/jop.2014.001527
46. Jung J, Xu WY, Cheong C. In-gap reductions in Medicare Half D and specialty drug use. Am J Manag Care. 2017;23(9):553-559.
47. Olszewski AJ, Dusetzina SB, Eaton CB, Davidoff AJ, Trivedi AN. Subsidies for oral chemotherapy and use of immunomodulatory medication amongst Medicare beneficiaries with myeloma. J Clin Oncol. 2017;35(29):3306-3314. doi:10.1200/jco.2017.72.2447
48. Shen C, Zhao B, Liu L, Shih Y-CT. Adherence to tyrosine kinase inhibitors amongst Medicare Half D beneficiaries with power myeloid leukemia. Most cancers. 2018;124(2):364-373. doi:10.1002/cncr.31050
49. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Value sharing and adherence to tyrosine kinase inhibitors for sufferers with power myeloid leukemia. J Clin Oncol. 2014;32(4):306-311. doi:10.1200/jco.2013.52.9123
50. Chen AB, Feng Y, Neuberg D, et al. Employment and insurance coverage in survivors of Hodgkin lymphoma and their siblings: a questionnaire research. Leuk Lymphoma. 2012;53(8):1474-1480. doi:10.3109/10428194.2012.660629
51. Smits-Seemann RR, Kaul S, Hersh AO, et al. ReCAP: gaps in insurance coverage protection for pediatric sufferers with acute lymphoblastic leukemia. J Oncol Pract. 2016;12(2):175-176; e207-e214. doi:10.1200/jop.2015.005686
52. Ramachandran V, Park KE, Shah JR, Duvic M. Prognosis of cutaneous T-cell lymphoma by insurance coverage kind earlier than and after the Inexpensive Care Act: a nationwide database research. Dermatol On-line J. 2019;25(11):13030/qt5n4481mk.
53. Smith EC, Ziogas A, Anton-Culver H. Affiliation between insurance coverage and socioeconomic standing and threat of superior stage Hodgkin lymphoma in adolescents and younger adults. Most cancers. 2012;118(24):6179-6187. doi:10.1002/cncr.27684
54. E&C investigation finds hundreds of thousands of Individuals enrolled in junk medical insurance plans which can be dangerous for customers & fly beneath the radar of state regulators. Information launch. Home Committee on Power & Commerce; June 25, 2020. Accessed January 31, 2021. https://energycommerce.
55. Goldstein JS, Switchenko JM, Behera M, Flowers CR, Koff JL. Insurance coverage standing impacts general survival in Burkitt lymphoma. Leuk Lymphoma. 2019;60(13):3225-3234. doi:10.1080/10428194.2019.1623884